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The airway acts as the first defense against inhaled pathogens and particulate matter from
the environment. One major way for the airway to clear inhaled foreign objects is through
mucociliary clearance (MCC), an important component of the respiratory innate immune
defense against lung disease. MCC is characterized by the upward movement of mucus by
ciliary motion that requires a balance between the volume and composition of the mucus,
adequate periciliary liquid (PCL) volume, and normal ciliary beat frequency (CBF). Airway
surface fluid (ASL) is a thin layer liquid that consists of the highly viscous mucus upper
“gel” layer, and the watery lubricating lower “sol” layer. Mucus production, secretion and
clearance are considered to play a critical role in maintenance of airway health because
it maintains hydration in the airway and traps particulates, bacteria, and viruses. Different
types of epithelial cells, including secretory cells, and ciliated cells, contribute to the MCC
function. Cigarette smoke (CS) contains chemicals and particulates that significantly affect
airway secretion. Active and passive CS-induced chronic obstructive pulmonary disease
(COPD) is frequently associated with hyperplasia of goblet cells and submucosal glands
(SMGs), thus increasing the secretory capacity of the airways that impairs MCC.
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CIGARETTE SMOKE AND SECOND HAND SMOKE (SHS)
Cigarette smoking (CS) is the single largest cause of preventable
disease, disability, and death globally. Tobacco use is a major risk
factor for heart attacks, strokes, chronic obstructive pulmonary
disease (COPD), and cancer. Approximately 90% of lung cancer
cases in the USA are attributed to cigarette smoking. Similarly,
the United States Centers for Disease Control and Prevention
describes tobacco use as “the single most important preventable
risk to human health in developed countries and an important
cause of premature death worldwide.” CS aerosols are highly
concentrated mixtures of particles and gases. This “gas/particle
partitioning” is the same type of physical, gas/liquid distribution
process by which an atmospheric gas, such as nitrogen, dissolves
in blood. When a CS aerosol is drawn into the respiratory tract
(RT), a portion of each compound of interest (e.g., nicotine)
will initially be in the gas phase, and a portion will be in the
particle phase. Both of these phases can serve as pathways for
the delivery of the compound to RT tissues include pharyngeal,
bronchial, or alveolar regions (Pankow, 2001). There are an esti-
mated 5000 different chemicals in tobacco smoke (Borgerding
and Klus, 2005; Thielen et al., 2008). Many of them are the most
significant source of toxic chemicals of chemically mediated dis-
ease in humans (Ezzati and Lopez, 2003; Fowles and Dybing,
2003). Most of these compounds are not present in the tobacco
plant but are formed when the cigarette burns. Many studies pro-
vide evidence of the relationship between the amount of exposure
to tar or CS and the risk for head and neck, lung and skin cancers.
The most known CS carcinogens include polynuclear aromatic
hydrocarbons (PAH), acrolein, and nitrosamines. The gas phase
of CS contains various gases including ammonia, carbon diox-
ide, carbon monoxide, hydrogen cyanide, and nitric oxide. The
particle phase contains important constituents of CS, such as tar,
nicotine, aromatic hydrocarbons, phenol, and cresol. The mean
size of CS particles is 0.1–0.5μm, so they are capable of reaching
small airways (Domagala-Kulawik, 2008). In addition, radioac-
tive carcinogens such as lead-210 (210Pb) and polonium-210
(210Po) linger in second-hand smoke (SHS), which is deeper
and longer than when inhaling cigarettes especially in an indoors
environment.
SHS is the inhalation of smoke, called passive smoking, or
environmental tobacco smoke (ETS), by persons other than the
intended “active” smoker. It occurs when CS permeates any envi-
ronment, causing its inhalation by people within that environ-
ment. SHS contains largely the same components as mainstream
smoke, but with varying concentrations. SHS has been shown to
produce more particulate-matter (PM) pollution than an idling
low-emission diesel engine and it contains not only the gas phase
of exhaled smoke, but also the products of combustion of a
cigarette. Therefore, persons exposed to SHS are exposed to up
to 50 times higher concentration of some chemicals than smokers
themselves (Domagala-Kulawik, 2008). Additionally, the smoke
can also enter the body through the skin, adding an additional
source of exposure.
HEALTH EFFECT OF SHS
Similar to active smoking, exposure to SHS is also a significant
health problem concern worldwide. SHS exposure increases non-
smokers’ risk of cardiovascular disease and stroke by inducing
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several proatherosclerotic changes, including endothelial damage
related to oxidative stress and inflammation, increased platelet
aggregation, and increased arterial stiffness (Venn and Britton,
2007; Jefferis et al., 2010). SHS is also linked to several diseases
of the lung, including cancer (Brownson et al., 2002; Hecht,
2006), and COPD (Eisner et al., 2006, 2009), asthma (Butz et al.,
2011). Furthermore, SHS is associated with an increased risk of
type 2 diabetes mellitus (Houston, 2006; Kowall et al., 2010) and
with neurocellular changes (Slotkin et al., 2006) in infants with
prenatal SHS exposure. Several studies show that causal asso-
ciations exist between SHS and sudden infant death syndrome,
acute respiratory infections, middle ear disease, asthma in chil-
dren, and coronary heart disease as well as lung and sinus cancers
in adults. Evidence is suggestive but not conclusive regarding a
causal relationship between SHS and many other diseases. SHS
is a major public health problem because more than 126 million
people in the United States are exposed to SHS. Comprehensive
bans on smoking in public lead to a reduction in overall expo-
sure to SHS for both adults and children (Menzies, 2011), but
the incidence of SHS exposure is still worrisome. SHS also con-
tributes to the development of COPD in non-smokers and signif-
icantly impairs their airway secretion and mucociliary clearance
(MCC).
MUCOCILIARY CLEARANCE
MCC is a self-clearingmechanism of the airway to remove inhaled
pathogens and particulates. The mechanisms of bronchial secre-
tion and MCC are critical components of lung innate immunity.
Bronchial secretions are mainly produced by goblet cells and
submucosal glands (SMGs), but also include small amounts of
surfactant from Clara cells and other fluids that are part of the
airway epithelium fluid. Cilium is present on respiratory surface
epithelium, bearing hair-shaped structures on its surface (cilia).
Cilia beat within a PCL layer with low viscosity for which PCL is
the “sol” layer with a height that approximates the length of the
outstretched cilia (about 7μm) and keeps mucus at an optimal
distance from the underlying epithelia, consequently affecting the
clearance of mucus (Knowles and Boucher, 2002; Tarran, 2004).
The airway epithelium fluid contains many antibacterial proteins
and peptides including lysozyme, lactoferrin, and β-defensins. On
the top of “sol” layer is a second viscous film of mucus “gel”
that traps foreign particles and microorganisms. Acute inflam-
matory or toxic stimuli can promote hypersecretion of mucus
mediated by a large variety of cytokines and chemokines. Within
the thin fluid film of mucus, the cilia act out movements coor-
dinated in a direction toward the pharynx. Therefore the vis-
cous film of mucus that includes its freight is transported off
in the direction of the mouth, where it is either swallowed or
expelled via coughing. The “gel” layer of the airway epithelium
fluid is formed mainly by water, mucins (MUC), and free pro-
teins. Mucins are highly glycosylated macromolecules. To date,
more than 21 different MUC-genes have been described, at least
eight of which are expressed in the RT, although MUC5AC and
MUC5B are the two main gel-forming mucins secreted in the
airway. Also important for good MCC are the number, struc-
ture, activity, and coordinated movement of cilia. Function of
ciliary cell is essential for MCC and ciliary cells may suspend
their transport function after a short time under the adverse
condition of insufficient temperature and humidity, which sub-
sequently facilitate bacterial germinal colonization. Inhaled SHS
contains PM and toxic chemicals that negatively impact MCC
by increasing mucus secretion and decreasing ciliated cell num-
bers and ciliary beat frequency (CBF). Pulmonary infections and
injury to the lung tissues in COPD patients may arise when the
MCC function is compromised.
LUNG EPITHELIAL CELLS AND MCC
In addition to acting as a physical barrier, airway epithelium
regulates fluid balance, modulates metabolism and clearance of
inhaled agents, and secretes numerous mediators (Knight and
Holgate, 2003). The MCC function is a coordinated action of
lung epithelial cells that include a variety of cell types such as
mucous, serous, goblet, ciliated, Clara, and basal cells (Figure 1).
Secretory cells located in airway epithelium and SMGs are an
important component of MCC mechanisms in the normal lung,
and alterations in the phenotype of these cells are associated with
the pathogenesis of several lung diseases. In human large air-
ways, goblet cells of the surface epithelium, as well as serous and
mucous cells of the glands, are the principal secretory cell types.
Serous and mucous cells may control the properties of the mucus
gel by regulating the ratio between secreted proteoglycans and
mucins. Airway glandular epithelium forms an integrated struc-
ture with functionally appropriate proportion of ciliated cells,
goblet cells, and basal cells. A proper ciliary movement improves
valid host defense and is necessary in the cleansing processes
of the airway epithelium. A brief description of major types of
epithelial cells is provided in the following paragraph and sum-
marized in Table 1. Effects of SHS on these cells and MCC will
then be discussed further.
Mucous cells are defined by electron-lucent acidic-mucin
granules that secrete mucus into the airway to trap foreign
objects such as pathogens and dust particles (Jeffery, 1983). The
mucous layer present in the airway from the level of the trachea
to the bronchioles consists of a mixture of highly glycosylated
mucin proteins. In the normal airways, there is a fine equilib-
rium between mucous production and clearance. However, in
chronic airway inflammatory diseases, such as chronic bronchitis
and asthma, mucous cell hyperplasia andmetaplasia occur, which
lead to excessive sputum production.
Goblet cells are simple columnar epithelial cells that share
multiple characteristics with mucous cells but are scattered
on the surface epithelium instead of located in the secretory
glands. The term goblet refers to these cells’ unique “goblet-like”
shape. The apical portion is shaped like a cup, as it is distended by
abundant mucinogen granules; its basal portion is shaped like a
stem, as it is narrow for lack of these granules. Goblet cell hyper-
plasia is a prominent feature in peripheral airways of smokers
with both symptoms of chronic bronchitis and chronic airflow
limitation (Wongsurakiat et al., 1998).
Serous cells are the most abundant secretory cells in human
airway glands (estimated serous/mucous cell volume ratio is
60%:40%) with variable numbers of electron-dense granules
that contain large quantities of enzymes. They have irregularly
shaped basally oriented nuclei, a perinuclear zone containing
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FIGURE 1 | Airway and epithelium.
Table 1 | Major cell types of respiratory tract epithelium.
Cell type Feature(s) Function(s) Location Marker(s)
Mucous
cells
Columnar mucus-secreting cells;
contain mucous electron-lucent,
acidic-mucin granules
Secret mucus Trachea, bronchi and
bronchioles
MUC5AC, MUC5B
Goblet
cells
Columnar mucus-secreting cells;
contain mucous electron-lucent
granules, which discharges apically.
More abundant in human airway
epithelium compared to the mouse
Contribute to airway mucus Bronchi; small
numbers in bronchioles
Present in acinar
region of SMGs
MUC5AC, MUC5B,
SPDEF
Serous
cells
Contain variable number of
electron-dense granules concentrated
in apical cytoplasm
Produce secretion of lower
viscosity than that from mucous
cells
Trachea, bronchi,
present in acinar region
of SMGs
Lysozyme,
Lactoferrin, ZAG,
SPLUNC1
Clara cells Columnar nonciliated bronchiolar cells
projecting in lumen; protuberant apical
cytoplasm with large, round
electron-dense secretory granules;
comprise the majority of nonciliated
bronchiolar cells
Secretory functions contributing
to the mucous pool and
maintaining extracellular lining
fluid; progenitor for other
bronchiolar cells
Predominantly in
bronchioles
CCSP SP-A, SP-B,
SP-D
Basal cells Short cells with relatively little
cytoplasm; oriented along the
basement membrane; stem cells of the
pseudostrafified airway epithelium
Regenerate the epithelium after
loss of luminal cells and
maintain it during homeostasis
Bronchi; rare in
bronchioles
TP63, KRT5, PDPN
and NGFR
Ciliated
epithelial
cells
Columnar, cuboidal, ciliated bronchial
lining cells; each cell has approximately
250–300 cilia at the apical surface, and
each cilium is approximately 6–7μm
long
Proximal transport of mucous
stream (mucociliary escalator)
Bronchi and
bronchioles
FOXJ1
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large quantities of rough endoplasmic reticulum (RER) required
for protein (enzyme) manufacture. Serous cells are the primary
defensive cells of the mucosa because they discharge bacterici-
dal compounds that deal efficiently with pathogens (Basbaum
and Jany, 1990; Joo et al., 2004). Serous cells secrete various
antibacterial proteins including lysozyme, lactoferrin, secretory
immunoglobin A, peroxidase, and protease inhibitors, many of
which are cationic in nature.
Clara cells contain electron-dense granules and are found
mostly in the small airways in humans (Knight and Holgate,
2003). To regulate bronchiolar epithelial integrity and immunity,
Clara cells have been shown to produce bronchiolar surfactants
and specific antiproteases, such as secretory leukocyte protease
inhibitor. In addition, Clara cells can produce p450 mono-
oxygenases (Dewater et al., 1986), which are able to metabolize
xenobiotic compounds such as aromatic hydrocarbons, which
are found in cigarette smoke (CS). Clara cells produce Clara cell
10-kDa protein, Clara cell 55-kDa protein, Clara cell tryptase,
galactoside-binding lectin, possibly a specific phospholipase, and
surfactant proteins A, B, and D.
Basal cells are highly abundant in both the upper and lower
airways (Boers et al., 1998). Basal cells have been demonstrated to
possess stem cell-like properties in that they can self-renew and
give rise to secretory and ciliated epithelial cells in response to
epithelial injuries (Hong et al., 2004). Thus, basal cells are thought
to be the progenitor cells of lung epithelium and are potentially
capable of differentiating and proliferating in many pathological
circumstances.
Ciliated epithelial cells are columnar epithelial cells with spe-
cialized ciliary modifications and are terminally differentiated
cells that originate in either basal or secretory cells (Ayers and
Jeffery, 1988). Usually, there are 250–300 cilia per cell and a large
number of mitochondria provide energy to the cilia for MCC via
proper ciliary beating. In general, cilia are sensory organelles and
motile cilia in the airway epithelium are the engine for MCC.
Ciliary beats provide the required physical force to move mucus
and the trapped foreign particles while the CBF determines the
flow speed of the movement. SHS decreases not only ciliated cells
and ciliogenesis but also CBF.
EFFECT OF SHS ON MCC
COPD is characterized by chronic obstruction of expiratory flow
affecting peripheral airways, associated with chronic bronchi-
tis (mucus hypersecretion with goblet cell and SMG hyperpla-
sia) and emphysema (destruction of pulmonary parenchyma),
together with fibrosis and tissue damage, and inflammation of
the small airways (Chung, 2001; Reid and Sallenave, 2003; Hogg
et al., 2004). Most COPD is caused by long-term active smok-
ing or SHS and it has been documented that smoke significantly
compromises MCC.Multiple toxins in SHS, including PM, oxida-
tive chemicals, and organic compounds inducemucin production
(Deshmukh et al., 2008) and excessive airwaymucus is a hallmark
feature of COPD. Airflow obstruction in COPD correlates with
changes in mucin gene expression, increases in goblet-cell num-
ber and size (Innes et al., 2006), the occlusion of small airways
with mucus (Sheehan et al., 1995), and expansion of the SMGs
(Hogg, 2004; Hogg et al., 2004). CS-induced MCC dysfunction
is complex and incompletely understood, but it involves adverse
effects on the structure and function of cilia (Verra et al.,
1995; Leopold et al., 2009; Tamashiro et al., 2009), activation
of ErbB receptors, and proinflammatory effects that increase
mucin production while decreasing mucus hydration and clear-
ance. It is suggested that a CS-decreased MCC in COPDmay lead
to airway infection, which subsequently leads to inflammation
and fibrosis.
One major characteristics of airway remodeling in COPD is
airway goblet cells metaplasia and hyperplasia, which results in
airway mucus hypersecretion. Airway goblet cell hyperplasia is a
prominent pathophysiological feature of COPD and is an often-
used end point in animal models of respiratory disease (Rogers,
1997). The cellular composition of the airway epithelium can be
altered both by cell division and by differentiation of one cell into
another (Ayers and Jeffery, 1988). In terms of goblet cell hyper-
plasia, differentiation is the major pathway for producing of new
goblet cells, and cell division is the major carcinogenic pathway.
The basal, serous and Clara cells are considered the primary pro-
genitor cells, because they have the capacity to undergo division,
followed by differentiation into “mature” ciliated or goblet cells.
In specific experimental conditions such as exposure to SHS, gob-
let cell division contributes in part to the hyperplasia. However,
differentiation of nongranulated airway epithelial cells is a major
route for production of new goblet cells (Rogers, 1994; Nadel
and Burgel, 2001). In experimental animals, production of gob-
let cells is usually at the “expense” of the progenitor cells, most
notably serous andClara cells, which decrease in number as goblet
cell numbers increase. Serous-like cells and Clara cells are found
in macroscopically normal bronchioles in human lung (Rogers
et al., 1993). The decreased numbers of serous and Clara cell has
pathophysiological importance because these cells produce a large
number of anti-inflammatory, immunomodulatory, and antibac-
terial molecules that are vital to host defense (Basbaum et al.,
1990; Singh and Katyal, 2000). Therefore, in CS-related respira-
tory diseases associated with airway mucus hypersecretion and
impaired MCC, it seems that not only is there goblet cell hyper-
plasia, with associated mucus hypersecretion, but also a reduction
in serous and Clara cells, with concomitant impaired potential for
host defense.
It has been supported by epidemiological data that mucus
hypersecretion is significantly associated with a more rapid
decline in FEV1 and increased hospitalization of patients with
COPD. Among all identified mucins, MUC5AC appears to be
the predominant mucin in healthy human airway epithelial
cells, and its expression is augmented in smokers and COPD
patients (Peter Di et al., 2012). CS induces mucin expression
in cultured human airway epithelial cells (Phillips et al., 2005;
Cortijo et al., 2011) and MUC5AC secretion can be regu-
lated by several inflammatory cytokines including TNF-α and
IL-13. The expression level of MUC5B is approximately 20%
of that seen for MUC5AC in airway epithelial cell and it is
secreted mainly by mucous cells in SMGs and partially by goblet
cells. Several mechanisms have been reported to be responsi-
ble for CS-induced mucus hypersecretion. First, CS could cause
mucin production via epidermal growth factor receptor (EGFR)
activation both in vitro and in vivo (Takeyama et al., 2001).
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Then, TNF-α-converting enzyme (TACE)-proligand-EGFR signal
pathway could also be involved in CS-induced mucin overpro-
duction (Shao et al., 2004). Furthermore, CS could promote
goblet cell metaplasia indirectly through activation and recruit-
ment of neutrophils and subsequent epithelial cell oxidative stress
(Fischer and Voynow, 2002). In vivo, neutrophils and neutrophil
products can cause the upregulation and release of mucin from
surface epithelial cells (Takeyama et al., 1998; Voynow et al.,
2004). EGF increased MUC5AC gene expression via ERK/MAP
kinase but not p38/MAP kinase in NCI-H292 cells (Takeyama
et al., 2000). Extracellular signal-regulated Kinase1/2 (ERK 1/2)
plays an important role in airway mucus hypersecretion induced
by CS in rats (Xiao et al., 2011).
In general, animal models have been essential to the devel-
opment of every drug and therapeutic used to treat of COPD.
One of important reasons for using animal models to tissues
and cells isolated from COPD patients is that animals provide
experimental settings that allow a clearer understanding of how
an active immune system interacts with whole respiratory sys-
tem. There are a large number of experimental researches on
drugs and therapies of COPD induced by CS in laboratory ani-
mals. These include celecoxib (Roh et al., 2010), simvastatin (Lee
et al., 2005), roflumilast (Martorana et al., 2005), neutrophil elas-
tase inhibitors or neutrophil elastase knockout (Wright et al.,
2002; Shapiro et al., 2003), matrix metalloprotease inhibitors
(Pemberton et al., 2005), α1-antitrypsin (Churg et al., 2003;
Pemberton et al., 2006), curcumin (Suzuki et al., 2009), and
overexpression of CuZnSOD (Foronjy et al., 2006), which all
prevent CS-induced inflammation and emphysema. However, not
all of the useful treatments in animal models have been used in
humans. Actually, no one animal species can accurately model
all features of human disease situations and humans normally
get treated when they have more severe and sophisticated COPD
than used experimentally in animal models. Current COPD ani-
mal models concentrate on emphysema rather than small airway
remodeling, the key cause of airflow obstruction. It should be
noted that small airway remodeling and emphysema are indepen-
dent symptoms of CS that could co-exist in COPD patients.
CONCLUSIONS
CS/SHS induces airway mucus hypersecretion and inflamma-
tion through various chemical components and signaling path-
ways. The significantly increasedmucus production and secretion
result in excess sputum that may promote airflow obstruction
and inflammation. CS/SHS exposure also results in composi-
tion changes in airway secretion and impairment of cilia beating
that are critical to a normal MCC. Increased mucin production,
decreased luminal liquid, and impaired cilia beating motion in
COPDhave deleterious consequences for airway health, including
mucus stasis and airway infection. CS/SHS-impairedMCC results
in the increased infection rate and disease severity that could be
associated with COPD exacerbations.
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